'Difficult to diagnose' desmoid tumours

A potential role for CTNNB1 mutational analysis

Chiara Colombo, Svetlana Bolshakov, Shohrae Hajibashi, Lola Lopez-Terrada, Wei Lien Wang, Priya Rao, Robert S. Benjamin, Alexander J. Lazar, Dina Lev

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Aims: The utility of CTNNB1 (encoding β-catenin) genotyping for diagnosing sporadic desmoid tumours (DT) when traditional clinicopathological parameters were inconclusive was evaluated. Methods and results: Cases included were: (i) new primary lesions where initial DT diagnosis was inconclusive; and (ii) possible recurrent DT versus scar. Formalin-fixed paraffin-embedded (FFPE) tissues were obtained via needle biopsy or a surgical excision (57 specimens) as part of initial assessment. DNA extraction, CTNNB1 exon 3 amplification and sequencing were conducted in a Clinical Laboratory Improvement Amendments of 1988 (CLIA)-approved molecular diagnostics laboratory. For patients with no previous DT history (n=47) sequencing identified mutations in 30 (64%), substantiating DT diagnosis. In biopsies with non-mutated (NM) CTNNB1 (n=17) the test was inconclusive; in seven of these, a diagnosis of DT was strongly favoured in the subsequent surgical resection specimen. Ten patients with previously resected DT were evaluated; mutation was identified in six cases (60%), indicating DT over scar. In two (20%) with primary tumours harbouring CTNNB1 mutation no mutation was found, favouring scar over DT; the other two NM-CTNNB1 cases (20%) were inconclusive. Conclusions: CTNNB1 genotyping can be very useful in 'difficult to diagnose' lesions when the differential diagnosis includes DT. Recognizing inherent test limitations, the presence of CTNNB1 mutation can inform the therapeutic approach.

Original languageEnglish
Pages (from-to)336-340
Number of pages5
JournalHistopathology
Volume59
Issue number2
DOIs
Publication statusPublished - Aug 2011

Fingerprint

Aggressive Fibromatosis
Neoplasms
Mutation
Cicatrix
Catenins
Molecular Pathology
Needle Biopsy
Paraffin
Formaldehyde
Exons
Differential Diagnosis
History

Keywords

  • β-catenin
  • CTNNB1
  • Desmoid tumour
  • Diagnostic tool
  • Sequencing

ASJC Scopus subject areas

  • Histology
  • Pathology and Forensic Medicine

Cite this

Colombo, C., Bolshakov, S., Hajibashi, S., Lopez-Terrada, L., Wang, W. L., Rao, P., ... Lev, D. (2011). 'Difficult to diagnose' desmoid tumours: A potential role for CTNNB1 mutational analysis. Histopathology, 59(2), 336-340. https://doi.org/10.1111/j.1365-2559.2011.03932.x

'Difficult to diagnose' desmoid tumours : A potential role for CTNNB1 mutational analysis. / Colombo, Chiara; Bolshakov, Svetlana; Hajibashi, Shohrae; Lopez-Terrada, Lola; Wang, Wei Lien; Rao, Priya; Benjamin, Robert S.; Lazar, Alexander J.; Lev, Dina.

In: Histopathology, Vol. 59, No. 2, 08.2011, p. 336-340.

Research output: Contribution to journalArticle

Colombo, C, Bolshakov, S, Hajibashi, S, Lopez-Terrada, L, Wang, WL, Rao, P, Benjamin, RS, Lazar, AJ & Lev, D 2011, ''Difficult to diagnose' desmoid tumours: A potential role for CTNNB1 mutational analysis', Histopathology, vol. 59, no. 2, pp. 336-340. https://doi.org/10.1111/j.1365-2559.2011.03932.x
Colombo, Chiara ; Bolshakov, Svetlana ; Hajibashi, Shohrae ; Lopez-Terrada, Lola ; Wang, Wei Lien ; Rao, Priya ; Benjamin, Robert S. ; Lazar, Alexander J. ; Lev, Dina. / 'Difficult to diagnose' desmoid tumours : A potential role for CTNNB1 mutational analysis. In: Histopathology. 2011 ; Vol. 59, No. 2. pp. 336-340.
@article{aba87fe2d19045b1b8dfa75a926818b9,
title = "'Difficult to diagnose' desmoid tumours: A potential role for CTNNB1 mutational analysis",
abstract = "Aims: The utility of CTNNB1 (encoding β-catenin) genotyping for diagnosing sporadic desmoid tumours (DT) when traditional clinicopathological parameters were inconclusive was evaluated. Methods and results: Cases included were: (i) new primary lesions where initial DT diagnosis was inconclusive; and (ii) possible recurrent DT versus scar. Formalin-fixed paraffin-embedded (FFPE) tissues were obtained via needle biopsy or a surgical excision (57 specimens) as part of initial assessment. DNA extraction, CTNNB1 exon 3 amplification and sequencing were conducted in a Clinical Laboratory Improvement Amendments of 1988 (CLIA)-approved molecular diagnostics laboratory. For patients with no previous DT history (n=47) sequencing identified mutations in 30 (64{\%}), substantiating DT diagnosis. In biopsies with non-mutated (NM) CTNNB1 (n=17) the test was inconclusive; in seven of these, a diagnosis of DT was strongly favoured in the subsequent surgical resection specimen. Ten patients with previously resected DT were evaluated; mutation was identified in six cases (60{\%}), indicating DT over scar. In two (20{\%}) with primary tumours harbouring CTNNB1 mutation no mutation was found, favouring scar over DT; the other two NM-CTNNB1 cases (20{\%}) were inconclusive. Conclusions: CTNNB1 genotyping can be very useful in 'difficult to diagnose' lesions when the differential diagnosis includes DT. Recognizing inherent test limitations, the presence of CTNNB1 mutation can inform the therapeutic approach.",
keywords = "β-catenin, CTNNB1, Desmoid tumour, Diagnostic tool, Sequencing",
author = "Chiara Colombo and Svetlana Bolshakov and Shohrae Hajibashi and Lola Lopez-Terrada and Wang, {Wei Lien} and Priya Rao and Benjamin, {Robert S.} and Lazar, {Alexander J.} and Dina Lev",
year = "2011",
month = "8",
doi = "10.1111/j.1365-2559.2011.03932.x",
language = "English",
volume = "59",
pages = "336--340",
journal = "Histopathology",
issn = "0309-0167",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - 'Difficult to diagnose' desmoid tumours

T2 - A potential role for CTNNB1 mutational analysis

AU - Colombo, Chiara

AU - Bolshakov, Svetlana

AU - Hajibashi, Shohrae

AU - Lopez-Terrada, Lola

AU - Wang, Wei Lien

AU - Rao, Priya

AU - Benjamin, Robert S.

AU - Lazar, Alexander J.

AU - Lev, Dina

PY - 2011/8

Y1 - 2011/8

N2 - Aims: The utility of CTNNB1 (encoding β-catenin) genotyping for diagnosing sporadic desmoid tumours (DT) when traditional clinicopathological parameters were inconclusive was evaluated. Methods and results: Cases included were: (i) new primary lesions where initial DT diagnosis was inconclusive; and (ii) possible recurrent DT versus scar. Formalin-fixed paraffin-embedded (FFPE) tissues were obtained via needle biopsy or a surgical excision (57 specimens) as part of initial assessment. DNA extraction, CTNNB1 exon 3 amplification and sequencing were conducted in a Clinical Laboratory Improvement Amendments of 1988 (CLIA)-approved molecular diagnostics laboratory. For patients with no previous DT history (n=47) sequencing identified mutations in 30 (64%), substantiating DT diagnosis. In biopsies with non-mutated (NM) CTNNB1 (n=17) the test was inconclusive; in seven of these, a diagnosis of DT was strongly favoured in the subsequent surgical resection specimen. Ten patients with previously resected DT were evaluated; mutation was identified in six cases (60%), indicating DT over scar. In two (20%) with primary tumours harbouring CTNNB1 mutation no mutation was found, favouring scar over DT; the other two NM-CTNNB1 cases (20%) were inconclusive. Conclusions: CTNNB1 genotyping can be very useful in 'difficult to diagnose' lesions when the differential diagnosis includes DT. Recognizing inherent test limitations, the presence of CTNNB1 mutation can inform the therapeutic approach.

AB - Aims: The utility of CTNNB1 (encoding β-catenin) genotyping for diagnosing sporadic desmoid tumours (DT) when traditional clinicopathological parameters were inconclusive was evaluated. Methods and results: Cases included were: (i) new primary lesions where initial DT diagnosis was inconclusive; and (ii) possible recurrent DT versus scar. Formalin-fixed paraffin-embedded (FFPE) tissues were obtained via needle biopsy or a surgical excision (57 specimens) as part of initial assessment. DNA extraction, CTNNB1 exon 3 amplification and sequencing were conducted in a Clinical Laboratory Improvement Amendments of 1988 (CLIA)-approved molecular diagnostics laboratory. For patients with no previous DT history (n=47) sequencing identified mutations in 30 (64%), substantiating DT diagnosis. In biopsies with non-mutated (NM) CTNNB1 (n=17) the test was inconclusive; in seven of these, a diagnosis of DT was strongly favoured in the subsequent surgical resection specimen. Ten patients with previously resected DT were evaluated; mutation was identified in six cases (60%), indicating DT over scar. In two (20%) with primary tumours harbouring CTNNB1 mutation no mutation was found, favouring scar over DT; the other two NM-CTNNB1 cases (20%) were inconclusive. Conclusions: CTNNB1 genotyping can be very useful in 'difficult to diagnose' lesions when the differential diagnosis includes DT. Recognizing inherent test limitations, the presence of CTNNB1 mutation can inform the therapeutic approach.

KW - β-catenin

KW - CTNNB1

KW - Desmoid tumour

KW - Diagnostic tool

KW - Sequencing

UR - http://www.scopus.com/inward/record.url?scp=80052229127&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052229127&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2559.2011.03932.x

DO - 10.1111/j.1365-2559.2011.03932.x

M3 - Article

VL - 59

SP - 336

EP - 340

JO - Histopathology

JF - Histopathology

SN - 0309-0167

IS - 2

ER -